Replies to post #145740 on Biotech Values

[iwfal]

SNTA -

Based on my experience working with oncology trials, it should be less than 10%, although that percentage could be higher among patients with short PFS duration as discussed in the first reply.

How much does that vary with cancer-type and treatment-type? Because the crude numbers (e.g. small trials, ...) I *have* seen were meaningfully higher than 10% but not necessarily in this disease.

[acgood]

Quote:
Do you have a cite (for percentage of PD events that are new lesion among NSCLC patients treated with docetaxel)?


No cite. Based on my experience working with oncology trials, it should be less than 10%, although that percentage could be higher among patients with short PFS duration as discussed in the first reply.

That is interesting to hear. SNTA was specific with a percentage, or specifically talking about docetaxel patients IMO. But they were acting like PD in advanced NSCLC was often associated with new lesions. I heard it as a general statement, but maybe it was just a comment on their data to date, which would be a very small number of patients.